Effects of enalaprilat on venoconstriction to norepinephrine: Role of prostaglandins

Cardiovascular Research

Volumn 59, Issue 1, 2003, Pages 250-256

  Dzeka, T Nancy ^a   Townley, Richard ^a   Arnold, J Malcolm O ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Clinical; Organism; Pharmacology; Vasculature

Indexed keywords

ENALAPRIL MALEATE; ENALAPRILAT; INDOMETACIN; NORADRENALIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; SODIUM CHLORIDE;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; ENZYME INHIBITION; FEMALE; HAND; HUMAN; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC TONE; VEIN; VENOCONSTRICTION;

ADULT; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENALAPRILAT; ENDOTHELIUM, VASCULAR; FEMALE; HAND; HUMANS; INDOMETHACIN; MALE; MIDDLE AGED; NOREPINEPHRINE; PROSTAGLANDINS; VASOCONSTRICTOR AGENTS;

EID: 0038771249     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00332-8     Document Type: Article

References (38)

1. Liu P., Arnold J.M.O., Belenkie I., et al. The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure. Can J Cardiol. 17:(Suppl E):2001;5-25.
2. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 38:2001;2101-2113.
3. Collaborative overview of randomised trials of antiplatelet therapy C1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 308:1994;81-106.
4. Hennekens C.H., Dyken M.L., Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 96:1997;2751-2753.
5. Cleland J.G.F., Bulpitt C.J., Falk R.H., et al. Is aspirin safe for patients with heart failure? Br Heart J. 74:1995;215-219.
6. Levine T.B., Francis G.S., Goldsmith S.R., Simon A.B., Cohn J.N. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 49:1982;1659-1666.
7. Lyons D., Roy S., O'Byrne S., Swift C.G. ACE inhibition: postsynaptic adrenergic sympatholytic action in men. Circulation. 96:1997;911-915.
8. Schror K. Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 20:(Suppl 9):1992;S68-S73.
9. Linz W., Wiemer G., Scholkens B.A. Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmacol. 22:(Suppl 9):1993;S1-S8.
10. Zarnke K.B., Feldman R.D. Direct angiotensin converting enzyme inhibitor-mediated venodilation. Clin Pharmacol Ther. 59:1996;559-568.
11. Kimura M., Umemura K., Kosuge K., et al. Attenuation by ACE inhibitor drugs of α-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity. Br J Clin Pharmacol. 46:1998;599-603.
12. Luscher T.F., Diederich D., Siebenmann R., et al. Difference between endothelium-dependent relaxation in arterial and venous coronary bypass grafts. New Engl J Med. 319:1988;462-472.
13. Haefeli W.E., Srivastava N., Kongpatanakul S., Blaschke T.F., Hoffman B.B. Lack of role of endothelium-derived relaxing factor in effects of α-adrenergic agonists in cutaneous veins in humans. Am J Physiol. 264:1993;H364-H369.
14. Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res. 35:1997;2-3.
15. Aellig W.H. Clinical pharmacology, physiology and pathophysiology of superficial veins C1. Br J Clin Pharmacol. 38:1994;181-196.
16. Dzeka T.N., Kuzminski P., Arnold J.M.O. Venous responsiveness to norepinephrine in healthy subjects: effects of single doses of 325 mg aspirin. Clin Pharmacol Ther. 67:2000;299-304.
17. Alradi A.O., Carruthers S.G. Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity. Clin Pharmacol Ther. 38:1985;495-502.
18. Yokoyama H., Minatoguchi S., Koshiji M., et al. Losartan and captopril follow different mechanisms to decrease pressor responses in the pithed rat. Clin Exp Pharmacol Physiol. 24:1997;697-705.
19. Licker M., Neidhart P., Lustenberger S., et al. Long-term angiotensin-converting enzyme inhibitor treatment attenuates adrenergic responsiveness without altering hemodynamic control in patients undergoing cardiac surgery. Anesthesiology. 84:1996;789-800.
20. 2-adrenoceptor-mediated venoconstriction with indomethacin in humans. Am J Physiol. 275:1998;H837-H843.
21. Hornig B., Kohler C., Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 95:1997;1115-1118.
22. Unger T., Gohlke P., Ganten D., Lang R.E. Converting enzyme inhibitors and their effects on the renin-angiotensin system of the blood vessel wall. J Cardiovasc Pharmacol. 13:(Suppl 3):1989;S8-S16.
23. Blackman D.J., Morris-Thurgood J.A., Atherton J.J., et al. Endothelium-derived nitric oxide contributes to the regulation of venous tone in humans. Circulation. 101:2000;165-170.
24. Koller A., Dornyei G., Kaley G. Flow-induced responses in skeletal muscle venules: modulation by nitric oxide and prostaglandins. Am J Physiol. 275:1998;H831-H836.
25. Donnelly R., Meredith P.A., Elliott H.L., Reid J.L. Kinetic-dynamic relations and individual responses to enalapril. Hypertension. 15:1990;301-309.
26. Collier J.G., Nachev C., Robinson B.F. Effect of catecholamines and other vasoactive substances on superficial hand veins in man. Clin Sci. 43:1972;455-467.
27. Burch R.M., Wise C., Halushka P.V. Prostaglandin independent inhibition of calcium transport by non-steroidal anti-inflammatory drugs: differential effects of carboxylic acids and piroxicam. J Pharmacol Exp Ther. 221:1983;84-91.
28. Jeremy J.Y., Mikhailidis D.P., Dandona P. Differential inhibitory potencies of non-steroidal antiinflammatory drugs on smooth muscle prostanoid synthesis. Eur J Pharmacol. 182:1990;83-89.
29. Hall D., Zeitler H., Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 20:1992;1549-1555.
30. Townend J.N., Doran J., Lote C.J., Davies M.K. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril. Br Heart J. 73:1995;434-441.
31. Nguyen K.N., Aursnes I., Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 79:1997;115-119.
32. Spaulding C., Charbonnier B., Cohen-Solal A., et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril. Results of a double-blind, randomized comparative trial. Circulation. 98:1998;757-765.
33. Schwartz D., Kornowski R., Lehrman H., et al. Combined effect of captopril and aspirin in renal hemodynamics in elderly patients with congestive heart failure. Cardiology. 81:1992;334-339.
34. van Wijngaarden J., Smit A.J., de Graeff P.A., et al. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 23:1994;240-245.
35. Baur L.H., Schipperheyn J.J., van der Laarse A., et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J. 73:1995;227-236.
36. 1-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation. 105:2002;627-632.
37. Vane J.R., Botting R.M. Pharmacodynamic profile of prostacyclin. Am J Cardiol. 75:1995;3A-10A.
38. Celermajer D.S. Endothelial dysfunction: Does it matter? Is it reversible? J Am Coll Cardiol. 30:1997;325-333.